Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362547234> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4362547234 abstract "<div><p>CLDN18.2 (Claudin18.2)-targeting therapeutic antibodies have shown promising clinical efficacy in approximately 30% of gastric cancers expressing high levels of CLDN18.2 and less pronounced activity in low expressing malignancies. Here, we report that ZL-1211 is a mAb targeting CLDN18.2 engineered to promote enhanced antibody-dependent cellular cytotoxicity (ADCC) with the goal of achieving more potent activity in a wider spectrum of high- and low-CLDN18.2 expressing tumors. ZL-1211 demonstrated more robust <i>in vitro</i> ADCC activity than clinical benchmark not only in CLDN18.2-high but also CLDN18.2-low expressing gastric tumor cell lines. Greater antitumor efficacy was also observed in mouse xenograft models. Natural killer (NK) cell played critical roles in ZL-1211 efficacy and NK-cell depletion abrogated ZL-1211–mediated ADCC activity <i>in vitro</i>. ZL-1211 efficacy <i>in vivo</i> was also dependent on the presence of an NK compartment. Strikingly, NK cells strongly induced an inflammatory response in response to ZL-1211 treatment, including increased IFNγ, TNFα, and IL6 production, and were recruited into tumor microenvironment in patient-derived gastric tumors expressing CLDN18.2 upon ZL-1211 treatment to lyse the tumor cells. Taken together, our data suggest that ZL-1211 more effectively targets CLDN18.2-high gastric cancers as well as -low expressing malignancies that may not be eligible for treatment with the leading clinical benchmark by inducing enhanced ADCC response and activating NK cells with robust inflammation to enhance antitumor efficacy. Clinical activity of ZL-1211 is currently under evaluation in a phase I clinical trial (NCT05065710).</p>Significance:<p>ZL-1211, anti-CLDN18.2 therapeutic antibody can target CLDN18.2-high as well as -low gastric cancers that may not be eligible for treatment with clinical benchmark. ZL-1211 treatment induces NK-cell activation with robust inflammation to further activate antitumor immunity in tumor microenvironment.</p></div>" @default.
- W4362547234 created "2023-04-06" @default.
- W4362547234 creator A5002601658 @default.
- W4362547234 creator A5005711039 @default.
- W4362547234 creator A5006380789 @default.
- W4362547234 creator A5012718640 @default.
- W4362547234 creator A5019842869 @default.
- W4362547234 creator A5027651796 @default.
- W4362547234 creator A5030576383 @default.
- W4362547234 creator A5035374461 @default.
- W4362547234 creator A5037183666 @default.
- W4362547234 creator A5041024410 @default.
- W4362547234 creator A5042947574 @default.
- W4362547234 creator A5045218258 @default.
- W4362547234 creator A5045830368 @default.
- W4362547234 creator A5046315753 @default.
- W4362547234 creator A5049458306 @default.
- W4362547234 creator A5064585221 @default.
- W4362547234 creator A5072906560 @default.
- W4362547234 creator A5083513455 @default.
- W4362547234 creator A5084676022 @default.
- W4362547234 creator A5085985235 @default.
- W4362547234 creator A5091310696 @default.
- W4362547234 date "2023-04-04" @default.
- W4362547234 modified "2023-10-16" @default.
- W4362547234 title "Data from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models" @default.
- W4362547234 doi "https://doi.org/10.1158/2767-9764.c.6550980.v1" @default.
- W4362547234 hasPublicationYear "2023" @default.
- W4362547234 type Work @default.
- W4362547234 citedByCount "0" @default.
- W4362547234 crossrefType "posted-content" @default.
- W4362547234 hasAuthorship W4362547234A5002601658 @default.
- W4362547234 hasAuthorship W4362547234A5005711039 @default.
- W4362547234 hasAuthorship W4362547234A5006380789 @default.
- W4362547234 hasAuthorship W4362547234A5012718640 @default.
- W4362547234 hasAuthorship W4362547234A5019842869 @default.
- W4362547234 hasAuthorship W4362547234A5027651796 @default.
- W4362547234 hasAuthorship W4362547234A5030576383 @default.
- W4362547234 hasAuthorship W4362547234A5035374461 @default.
- W4362547234 hasAuthorship W4362547234A5037183666 @default.
- W4362547234 hasAuthorship W4362547234A5041024410 @default.
- W4362547234 hasAuthorship W4362547234A5042947574 @default.
- W4362547234 hasAuthorship W4362547234A5045218258 @default.
- W4362547234 hasAuthorship W4362547234A5045830368 @default.
- W4362547234 hasAuthorship W4362547234A5046315753 @default.
- W4362547234 hasAuthorship W4362547234A5049458306 @default.
- W4362547234 hasAuthorship W4362547234A5064585221 @default.
- W4362547234 hasAuthorship W4362547234A5072906560 @default.
- W4362547234 hasAuthorship W4362547234A5083513455 @default.
- W4362547234 hasAuthorship W4362547234A5084676022 @default.
- W4362547234 hasAuthorship W4362547234A5085985235 @default.
- W4362547234 hasAuthorship W4362547234A5091310696 @default.
- W4362547234 hasBestOaLocation W43625472342 @default.
- W4362547234 hasConcept C109316439 @default.
- W4362547234 hasConcept C121608353 @default.
- W4362547234 hasConcept C126322002 @default.
- W4362547234 hasConcept C159654299 @default.
- W4362547234 hasConcept C185592680 @default.
- W4362547234 hasConcept C202751555 @default.
- W4362547234 hasConcept C203014093 @default.
- W4362547234 hasConcept C40677261 @default.
- W4362547234 hasConcept C502942594 @default.
- W4362547234 hasConcept C542903549 @default.
- W4362547234 hasConcept C54355233 @default.
- W4362547234 hasConcept C55493867 @default.
- W4362547234 hasConcept C71924100 @default.
- W4362547234 hasConcept C81885089 @default.
- W4362547234 hasConcept C86803240 @default.
- W4362547234 hasConceptScore W4362547234C109316439 @default.
- W4362547234 hasConceptScore W4362547234C121608353 @default.
- W4362547234 hasConceptScore W4362547234C126322002 @default.
- W4362547234 hasConceptScore W4362547234C159654299 @default.
- W4362547234 hasConceptScore W4362547234C185592680 @default.
- W4362547234 hasConceptScore W4362547234C202751555 @default.
- W4362547234 hasConceptScore W4362547234C203014093 @default.
- W4362547234 hasConceptScore W4362547234C40677261 @default.
- W4362547234 hasConceptScore W4362547234C502942594 @default.
- W4362547234 hasConceptScore W4362547234C542903549 @default.
- W4362547234 hasConceptScore W4362547234C54355233 @default.
- W4362547234 hasConceptScore W4362547234C55493867 @default.
- W4362547234 hasConceptScore W4362547234C71924100 @default.
- W4362547234 hasConceptScore W4362547234C81885089 @default.
- W4362547234 hasConceptScore W4362547234C86803240 @default.
- W4362547234 hasLocation W43625472341 @default.
- W4362547234 hasLocation W43625472342 @default.
- W4362547234 hasOpenAccess W4362547234 @default.
- W4362547234 hasPrimaryLocation W43625472341 @default.
- W4362547234 hasRelatedWork W1949248222 @default.
- W4362547234 hasRelatedWork W1967470546 @default.
- W4362547234 hasRelatedWork W2094936714 @default.
- W4362547234 hasRelatedWork W2295265813 @default.
- W4362547234 hasRelatedWork W2365193933 @default.
- W4362547234 hasRelatedWork W2411420606 @default.
- W4362547234 hasRelatedWork W2417631503 @default.
- W4362547234 hasRelatedWork W2418656659 @default.
- W4362547234 hasRelatedWork W2464301138 @default.
- W4362547234 hasRelatedWork W2737440291 @default.
- W4362547234 isParatext "false" @default.
- W4362547234 isRetracted "false" @default.
- W4362547234 workType "article" @default.